Vion Pharmaceuticals announced that it would suspend enrollment and further patient treatment in its Phase III clinical study of Cloretazine (VNP40101M) for patients with relapsed adult myelogenous leukemia (AML) pending a detailed review of all of the data from the trial. This decision was based on the recommendation of the trial's independent Data Safety Monitoring Board (DSMB) after a planned interim analysis.

Starting new longterm uptrend

Recent accumulation by institution and insiders
Vion has two agents in clinical trials. Cloretazine® (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine® (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies

Cancer drug trials

Speculative cancer treatment play.

I could not believe that something could go that bad

it was to make money an d it didn't